Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
147.5 USD | +0.02% |
|
+3.67% | +11.92% |
09/07 | RBC Cuts Price Target on Neurocrine Biosciences to $136 From $141, Keeps Sector Perform Rating | MT |
03/07 | ANALYST RECOMMENDATIONS : Alphabet, Nike, Nvidia, Tesla, Starbucks... | ![]() |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.92% | 1.48TCr | |
+20.63% | 13TCr | |
+25.01% | 2.77TCr | |
-20.17% | 2.03TCr | |
-17.15% | 1.68TCr | |
-18.07% | 1.56TCr | |
-47.70% | 1.46TCr | |
+58.32% | 1.44TCr | |
+149.98% | 1.25TCr | |
-10.27% | 984.15Cr |
- Stock Market
- Equities
- NBIX Stock
- News Neurocrine Biosciences, Inc.
- RBC Cuts Price Target on Neurocrine Biosciences to $136 From $141, Keeps Sector Perform Rating